GlassScriptPhysician profile
Khin Gyi
NPI 1952461832
$1,570.66
in general payments reported to CMS, 2019-2025
10 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $181 · 2023: $360 · 2024: $885 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $351.30 | 2023-2024 | Soliris, Ultomiris |
| Grifols USA, LLC | $258.01 | 2022-2023 | Gamunex-C |
| Teva Pharmaceuticals USA, INC. | $248.68 | 2024 | Austedo Xr, Ajovy |
| Alnylam Pharmaceuticals INC. | $143.70 | 2025 | Amvuttra |
| Insightec,INC | $141.34 | 2024 | Exablate |
| Eisai INC. | $125.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $116.66 | 2024 | |
| Genzyme Corporation | $111.93 | 2023 | |
| Grt US Holding, INC. | $54.77 | 2022 | |
| Ucb, INC. | $19.27 | 2023 | Fintepla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khin Gyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.